TD Cowen reiterates Buy on Affirm stock, sees GMV above guidance

TD Cowen reiterated a Buy rating on Affirm with an $80 price target versus a $67.51 share price, ahead of earnings in two days. The firm sees Q3 fiscal 2026 GMV slightly above the top end of guidance, while alternative data shows 29.8% March-quarter sales growth and 30.0% growth to date in the June quarter, though that is slower than the prior quarter's 36.0% growth. Affirm also completed two securitizations totaling $1.75 billion, with analyst views still broadly positive despite a mixed valuation backdrop.

Analysis

AFRM’s setup into earnings is less about whether growth is still good and more about whether the market has already priced the deceleration correctly. The key second-order effect is that credit investors are still willing to fund the balance sheet at tight spreads, which lowers funding friction and supports continued merchant/member acquisition even if top-line growth cools a bit. That matters because the stock likely trades on confidence in a durable funding flywheel, not just a single quarter of GMV.

The consensus risk is that investors overweight the modest March-quarter slowdown and underweight the durability of the June-quarter run-rate. If the company merely confirms mid-30s growth with no deterioration in loss trends, the multiple can expand quickly because positioning is likely cautious after the recent run and valuation screens are still labeling the name expensive. The bigger threat is not demand but a miss on contribution margin or credit performance, which would force the market to reprice the idea that AFRM is entering a more self-funding phase.

For Morgan Stanley, the relevance is indirect: if AFRM’s securitizations continue clearing cleanly, it is a data point that private credit stress is not yet contaminating adjacent consumer-finance funding markets. That can help stabilize broader fintech sentiment and reduce the discount rate applied to growth lenders. Conversely, any widening in spreads or a weak forward guide would quickly spill into the entire higher-beta payments complex.

The contrarian read is that the market may be too focused on absolute growth deceleration and not enough on the mix of growth quality. If purchase frequency and approval economics are improving, slightly slower GMV can still translate into better unit economics and a higher terminal multiple. This makes the report a potential upside catalyst if management emphasizes profitability trajectory rather than just volume growth.

Key Decisions for Investors

• Tactically long AFRM into earnings via common or near-dated calls; the setup favors a 2-3 week catalyst trade if guidance/credit commentary is merely in-line to slightly better, with upside likely larger than the downside from a small GMV miss.
• If already long AFRM, pair with a short in a higher-beta fintech basket or index proxy to isolate company-specific earnings upside while reducing market factor risk over the next 1-2 weeks.
• Buy AFRM downside puts only if management language suggests securitization spreads are widening materially or 4Q growth is decelerating faster than expected; otherwise implied volatility may be overstating tail risk.
• Watch consumer-credit and private-credit proxies over the next 30-60 days; a clean AFFIRM print supports longs in adjacent growth lenders, while a funding blemish argues for reducing exposure across the group.
• Post-earnings, if AFRM gaps up on clean execution, consider selling upside into strength rather than chasing, because the stock likely needs repeated beats to justify multiple expansion at current levels.